Quick Reference for Clinical Decision-Making
The 2024 ESC Guidelines emphasize more aggressive LDL-C lowering in patients with PAD:
PCSK9 inhibitors are now recommended earlier for PAD patients not at LDL goal with statin + ezetimibe. Consider inclisiran (bempedoic acid) for those with statin intolerance.
Rivaroxaban (2.5 mg BID) plus aspirin has demonstrated cardiovascular benefit in stable PAD:
1Supervised exercise therapy is the first-line treatment for intermittent claudication. Minimum 30 minutes, 3×/week for 12 weeks.
Enhanced diagnostic algorithms and risk stratification for acute aortic syndromes including penetrating aortic ulcers and intramural hematomas with management recommendations.
This guideline uses the ESC/EAS classification system for recommendations:
| Class of Recommendation | Definition |
|---|---|
| I | Evidence and/or general agreement that given treatment/procedure is beneficial, useful, effective |
| IIa | Weight of evidence/opinion is in favor of usefulness/efficacy |
| IIb | Usefulness/efficacy less well established; may be considered |
| III | Evidence or consensus that treatment is not useful/effective and may be harmful |
| Level of Evidence | Definition |
|---|---|
| A | Data derived from multiple randomized clinical trials or meta-analyses |
| B | Data derived from a single randomized clinical trial or large non-randomized studies |
| C | Consensus opinion of experts and/or small studies, retrospective studies, registries |
ISmoking cessation is essential for all patients with PAD or aortic disease. It remains the most cost-effective intervention for reducing progression and cardiovascular events.
ITarget systolic BP 120-129 mmHg in most PAD patients to reduce cardiovascular events while minimizing symptomatic hypotension.
IAchieve LDL-C reduction of ≥50% from baseline, with goals:
IUse GLP-1 receptor agonists or SGLT2 inhibitors in diabetic PAD patients for cardiovascular and renal benefits.
Focusing only on HbA1c control without addressing other ASCVD risk factors. Comprehensive risk factor modification is essential in diabetic PAD patients.
IABI is the first-line diagnostic test for PAD. Interpretation:
| ABI Value | Interpretation |
|---|---|
| ≥1.40 | Non-compressible arteries (calcification); repeat with toe-brachial index |
| 1.00-1.39 | Normal |
| 0.91-0.99 | Borderline; consider TBI or imaging if symptomatic |
| 0.71-0.90 | Mild-moderate PAD |
| 0.41-0.70 | Moderate-severe PAD |
| ≤0.40 | Severe PAD; high risk of CLTI |
IIaConsider TBI (normal >0.70) and transcutaneous oxygen pressure (TcPO₂ >40 mmHg healing potential) in patients with non-compressible ABI or to assess wound healing.
| Modality | Indications | Advantages | Limitations |
|---|---|---|---|
| Duplex Ultrasound | First imaging after ABI abnormality; screening | No radiation, fast, reproducible | Operator dependent; limited by obesity/calcification |
| CT Angiography | Preoperative planning; acute limb ischemia | Fast, high sensitivity, calcification assessment | Radiation; contrast nephropathy risk |
| MR Angiography | Renal insufficiency (non-contrast); PAD assessment | No ionizing radiation; tissue characterization | Contraindicated with MRI-incompatible devices; motion artifact |
| Angiography | When intervention planned | Gold standard; enables intervention | Invasive; contrast/procedural risk |
IAspirin 75-100 mg daily is standard for stable PAD.
IIaRivaroxaban 2.5 mg BID plus aspirin for additional cardiovascular benefit (COMPASS trial).
Clopidogrel 75 mg daily is reserved for aspirin-intolerant patients.
Measure BP systematically
↓
Target: Systolic 120-129 mmHg
↓
First-line: ACE-I or ARB
↓
Goal not met? → Add CCB or thiazide-like diuretic
↓
Still not at goal? → Combine three agents
↓
Monitor renal function and potassium (esp. if ACE-I/ARB)
IHigh-intensity statin (atorvastatin 80 mg or rosuvastatin 40 mg daily)
IAdd ezetimibe 10 mg daily if LDL-C not at goal after 4-12 weeks
IIaPCSK9 inhibitor if LDL-C remains above goal after statin + ezetimibe
ISupervised aerobic exercise 30-60 minutes, 3×/week for 12+ weeks for intermittent claudication.
Exercise therapy is superior to many pharmacological interventions for claudication and should be first-line before revascularization in stable PAD with claudication.
| Fontaine Stage | Rutherford Category | Clinical Presentation |
|---|---|---|
| I | 0 | Asymptomatic (abnormal ABI) |
| II | 1-3 | Intermittent claudication |
| III | 4 | Rest pain |
| IV | 5-6 | Tissue loss/gangrene |
Confirm PAD diagnosis (ABI <0.90)
↓
Optimal medical management (statin, ACE-I/ARB, antiplatelet)
↓
Supervised exercise therapy 12 weeks
↓
Symptom improvement?
Yes → Continue exercise, medical mgmt
No → Consider revascularization
↓
Angiography (ultrasound or CTA first if available)
↓
Lesion anatomy suitable for intervention?
Yes → Endovascular ± surgical
No → Continued medical management
IIaRevascularization may be considered in limiting claudication after failed exercise therapy with appropriate anatomy.
IIaDual antiplatelet therapy (aspirin + clopidogrel) for 1 month post-PTA/stent in claudication; continue aspirin indefinitely.
Stent-specific considerations:
ICLTI is defined as rest pain, tissue loss (ulcer, gangrene), or both, with objective evidence of PAD (ABI ≤0.6 or TBI ≤0.4 or TcPO₂ ≤30 mmHg).
| WiFi Class | Wound | Ischemia | Foot Infection |
|---|---|---|---|
| 0 | No ulceration | - | - |
| 1 | Small ulcer | Mild ischemia | No infection |
| 2 | Small-moderate ulcer | Moderate ischemia | Mild-moderate infection |
| 3 | Large ulcer/gangrene | Severe ischemia | Severe infection |
Diagnose CLTI (ABI ≤0.6 or TBI ≤0.4)
↓
Assess wound healing potential (TcPO₂, perfusion)
↓
Infection present? → Antibiotics, wound care
↓
Revascularization candidate?
Yes → Angiography (ultrasound/CTA first)
No → Amputation + prosthetics ± palliative care
↓
Suitable anatomy for intervention?
Yes → Endovascular (first choice) or bypass
No → Amputation
↓
Post-intervention: Continue medical management, wound care
↓
Monitor for restenosis; repeat imaging if deterioration
IRevascularization (endovascular preferred) is indicated for CLTI to prevent amputation, even with multiple failed attempts.
IAggressive medical management alongside revascularization:
Delaying revascularization while "optimizing" the wound. In CLTI, revascularization should not be delayed; proceed with angiography even if infection is present (use antibiotics concurrently).
| Category | Viability | Sensorimotor Changes | Muscle Weakness |
|---|---|---|---|
| I (Viable) | Viable | None | None |
| II (Threatened) | Salvageable with prompt treatment | Mild-moderate | Mild-moderate |
| III (Irreversible) | Irreversible damage | Sensory loss; muscle paralysis | Profound |
Acute limb ischemia presentation (pain, pallor, pulselessness)
↓
Assess viability (Category I, II, or III)
↓
Heparinize immediately (except if Category III)
↓
Imaging (CTA or angiography preferred over duplex)
↓
Category I/II (viable/threatened):
Embolism → Catheter thrombectomy (preferred)
Thrombosis on PAD → Thrombolysis (if no contraindication) or thrombectomy
Consider hybrid approach (thrombolysis + mechanical)
↓
Category III (irreversible):
→ Amputation ± symptom management
↓
Post-intervention: Anticoagulation, monitor for reperfusion syndrome
IImmediate heparinization and urgent revascularization (catheter thrombectomy or thrombolysis) for viable/threatened limbs.
IIaCatheter-directed thrombolysis may be considered in Category II ischemia (threatened limb) to salvage tissue and improve outcomes.
IIIDo not attempt revascularization in Category III (irreversible); proceed to amputation and palliative care.
| NASCET Stenosis | Clinical Significance |
|---|---|
| <50% | No intervention; antiplatelet therapy |
| 50-69% | CEA/CAS for symptomatic; medical Rx for asymptomatic |
| ≥70% | CEA/CAS for symptomatic; consider intervention for asymptomatic |
| Factor | CEA Preferred | CAS Preferred |
|---|---|---|
| Age | <75 years | ≥75 years (relative) |
| Anatomy | Standard bifurcation | High, tortuous, kinked, contralateral stenosis |
| Cardiac Risk | High (CEA safer) | Low |
| Prior Neck Surgery | Relative contraindication | Preferred |
IIbConsider screening asymptomatic individuals with risk factors (smoking, hypertension, age >65, hyperlipidemia) or known ASCVD.
Routine screening of all asymptomatic elderly is not recommended.
The benefit of intervention in asymptomatic carotid disease is modest (~1% absolute risk reduction per year). Shared decision-making, patient preferences, and life expectancy should guide management.
IIaDuplex ultrasound or CTA/MRA is recommended for screening in patients with resistant hypertension, acute coronary syndrome, or flash pulmonary edema.
Identify RAS (imaging: duplex, CTA, MRA)
↓
Assess severity and blood pressure response
↓
<70% stenosis:
→ Medical management (ACE-I/ARB, statin, antiplatelet)
→ Monitor renal function
↓
≥70% stenosis or hemodynamically significant:
→ Renal artery stenting if:
- Uncontrolled BP despite 3+ medications
- Recurrent acute pulmonary edema
- Declining renal function
→ Avoid if eGFR <30 mL/min and no other indication
↓
Post-intervention: Continue medical management; monitor BP and renal function
IIaRevascularization (renal artery stenting) may be considered in RAS ≥70% with uncontrolled hypertension or declining renal function.
IMedical management (ACE-I/ARB, statin, antiplatelet therapy, BP control) is first-line for all patients with RAS.
Stenting asymptomatic RAS found incidentally. RAS is a progressive condition; medical management is usually adequate. Reserve stenting for clinically significant lesions with hypertension or renal dysfunction.
IAll patients with established ASCVD should be screened for aortic disease (AAA, TAD) with imaging.
IPatients with hypertension, smoking history, or family history of aortic disease should be offered screening ultrasound for AAA.
| AAA Diameter | Surveillance Interval | Repair Threshold |
|---|---|---|
| <3.0 cm | Baseline ultrasound only (low risk) | - |
| 3.0-4.4 cm | Annual ultrasound | Elective repair if ≥5.5 cm |
| 4.5-5.4 cm | Every 6 months | Elective repair if ≥5.5 cm or rapid growth (>0.5 cm/year) |
| ≥5.5 cm | Urgently plan repair | Elective repair indicated |
IIaAnnual or biennial imaging (CT or MRI) is recommended for thoracic aortic aneurysm 4.0-5.0 cm in diameter.
Repair thresholds vary by etiology (Marfan syndrome: 4.5-5.0 cm; bicuspid aortic valve: 5.0-5.5 cm).
IBeta-blockers or ARBs to reduce aortic wall stress (target HR 60 bpm, BP 120-130 mmHg systolic).
IStatin therapy and smoking cessation in all patients with aortic disease.
Modern surveillance imaging (CT with volumetric analysis) is superior to diameter measurement alone for predicting rupture risk. Consider volumetric growth in decision-making.
Acute aortic syndromes include type A and B aortic dissection (AD), intramural hematoma (IMH), penetrating aortic ulcer (PAU), and traumatic aortic transection.
| Feature | Type A (Ascending Aorta) | Type B (Descending Aorta) |
|---|---|---|
| Location | Involves ascending aorta ± arch/descending | Descending aorta, distal to left subclavian artery |
| Management | EMERGENCY surgery (aortic root replacement ± CABG/valve repair) | Medical management initially; surgery for complications |
| In-Hospital Mortality | 5-10% (with surgery) | 2-4% (medical management) |
Acute onset severe chest/back pain + risk factors
↓
High clinical suspicion? → Urgent imaging
↓
Imaging choice:
Type A (ascending aorta involved):
→ CT angiography or TEE
→ Immediate cardiothoracic surgery consultation
Type B (descending only):
→ CT angiography (gold standard)
→ Consider MRI if renal insufficiency (non-contrast)
↓
Confirm diagnosis and involvement of branches:
- Aortic root/valve compromise?
- Coronary ostium involvement?
- Branch vessel compromise (carotid, SMA, renal)?
↓
Type A → Emergency surgery
Type B uncomplicated → Medical management
Type B complicated → Endovascular or surgical repair
IEMERGENCY surgical intervention (aortic root replacement, Bentall procedure, or valve-sparing root repair) is essential for Type A dissection.
IInitial medical management with aggressive BP control (target SBP 120 mmHg) and beta-blockers (target HR 60 bpm).
IIMH/PAU involving ascending aorta should be treated similar to Type A dissection (urgent surgery).
IIaType B IMH/PAU may be managed medically with imaging surveillance if no signs of instability or progression.
IMH and PAU have heterogeneous outcomes. Close imaging follow-up is essential; ≈10% progress to frank dissection or rupture, requiring intervention. Do not assume all can be managed medically.
IAll patients with confirmed or suspected Marfan syndrome should be evaluated for aortic root dilation with echocardiography or CT/MRI.
| Aortic Root Diameter | Surveillance Interval | Beta-Blocker/ARB | Repair Threshold |
|---|---|---|---|
| <4.0 cm | Annual | Yes (losartan preferred) | - |
| 4.0-4.9 cm | Every 6 months | Yes (losartan preferred) | Repair if ≥5.0 cm or rapid growth |
| ≥5.0 cm | Urgent surgical consultation | Yes (optimize before surgery) | Elective repair indicated |
IPatients with BAV should be screened for aortic dilation and followed with echocardiography or CT/MRI.
IPatients with Turner syndrome should undergo baseline cardiac assessment (echocardiography, MRI) for aortic root diameter and coarctation.
IIaEhlers-Danlos syndrome (especially vascular type), familial aortic aneurysm, and hereditary thoracic aortic diseases warrant imaging surveillance and genetic counseling.
Losartan has been shown to slow aortic dilation in Marfan syndrome better than beta-blockers alone. Use ARBs as first-line in connective tissue disorders with aortic involvement.
The following calculators are recommended for risk assessment and treatment decision-making in peripheral arterial and aortic disease management:
AHA/ACC 10-year ASCVD risk calculator; useful for treatment intensity decisions in preventive cardiology.
Classic 10-year CHD risk prediction tool; still used in some regions for risk stratification.
Lifetime cardiovascular risk estimation; motivates prevention in younger patients with low 10-year risk.
10-year CHD risk with optional coronary artery calcium integration; reclassifies intermediate-risk patients.
Estimates LDL-C reduction needed to achieve guideline targets; helps select appropriate therapy intensity.
Estimated cardiovascular age based on risk factor burden; communicates prevention urgency to patients.
CKD-EPI 2021 equation for GFR estimation; essential for medication dosing in renal insufficiency.
Creatinine clearance calculator; some medications still dosed using this equation.
Stroke risk assessment in atrial fibrillation; relevant for PAD patients with concurrent AF.
These tools are most effective when used as part of a structured shared decision-making conversation with patients. Integrate risk calculators into your EHR when possible to streamline workflow and improve guideline adherence.
Relying on a single risk calculator without considering patient context. Use multiple calculators for comprehensive risk assessment; they may provide complementary information.
Disclaimer: This is a clinical quick reference based on the 2024 ESC Guidelines on Peripheral Arterial and Aortic Diseases. Always consult the full guideline document and exercise clinical judgment when making patient management decisions. This resource is for educational purposes and should not replace professional medical judgment.